← Back to Search

Virus Therapy

Lenacapavir for HIV Prevention (PURPOSE 2 Trial)

Phase 3
Waitlist Available
Research Sponsored by Gilead Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks
Timeline
Screening 3 weeks
Treatment Varies
Follow Up when all participants have completed a minimum of 52 weeks of follow-up in the study, or permanent discontinuation, whichever occurs first (maximum approximately 130 weeks)
Awards & highlights

PURPOSE 2 Trial Summary

This trial will study the effectiveness of a new drug, lenacapavir, in preventing HIV infection in people who are at risk. The trial will have two parts: a cross-sectional study to estimate the background HIV infection rate, and a double-blind, randomized study to study the drug.

Who is the study for?
This trial is for individuals at risk of HIV infection who have had condomless receptive anal sex with male partners, used stimulants during sex recently, or had certain sexually transmitted infections. They must have a kidney function test result (eGFR) ≥ 60 mL/min and not previously taken long-acting PrEP or oral PrEP in the past 12 weeks.Check my eligibility
What is being tested?
The study tests Lenacapavir's effectiveness in preventing HIV. Participants will receive either oral Lenacapavir, subcutaneous Lenacapavir, placebos, or other pre-exposure prophylaxis drugs like F/TDF (and F/TAF for US participants).See study design
What are the potential side effects?
Potential side effects of Lenacapavir include injection site reactions for the subcutaneous form and gastrointestinal issues such as nausea or diarrhea. Other general side effects may include fatigue and headache.

PURPOSE 2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am at risk for HIV due to unprotected sex with male partners.
Select...
I've had unprotected receptive anal sex with 2 or more partners in the last 3 months.
Select...
My kidney function, measured by eGFR, is 60 mL/min or higher.
Select...
I am at risk for HIV due to unprotected sex.
Select...
I've had unprotected receptive anal sex with 2 or more partners in the last 3 months.
Select...
I have had syphilis, rectal gonorrhea, or rectal chlamydia in the past 6 months.
Select...
My kidney function, measured by eGFR, is 60 mL/min or higher.

PURPOSE 2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at screening
This trial's timeline: 3 weeks for screening, Varies for treatment, and at screening for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence Phase: Background HIV Incidence per 100-Person-Years (PY)
Randomized Phase: Number of Participants with Diagnosis of HIV-1 Infection
Secondary outcome measures
Number of Participants with Diagnosis of HIV Among Participants While Adherent to Study Drug
Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities
Percentage of Participants Experiencing Treatment-Emergent Adverse Events

PURPOSE 2 Trial Design

4Treatment groups
Experimental Treatment
Group I: PK Tail PhaseExperimental Treatment2 Interventions
At the completion of the LEN OLE phase, participants will transition into the PK Tail phase. Additionally, participants that prematurely discontinue the study drug during blinded phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase are also eligible to transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks beginning 26 weeks after the last injection of LEN.
Group II: LEN Open-Label Extension (OLE) PhaseExperimental Treatment2 Interventions
After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase. Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses. Participants randomized to F/TDF will receive SC LEN 927 mg on OLE Day 1, OLE Week 26, and will also receive oral LEN 600 mg on OLE Days 1 and 2.
Group III: Blinded Phase: Placebo LEN + F/TDFExperimental Treatment3 Interventions
Participants will receive the following for at least 52 weeks: SC LEN placebo every 26 weeks Oral F/TDF 200/300 mg once daily PTM Oral LEN on Days 1 and 2 Participants will receive oral LEN placebo if SC injections are not available
Group IV: Blinded Phase: LEN + Placebo-to-match (PTM) F/TDFExperimental Treatment3 Interventions
Participants will receive the following for at least 52 weeks: Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily Oral LEN 600 mg on Days 1 and 2 Participants will receive oral LEN if SC injections are not available
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
F/TDF
2018
Completed Phase 3
~250

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor
1,082 Previous Clinical Trials
839,546 Total Patients Enrolled
1 Trials studying Pre-Exposure Prophylaxis
57 Patients Enrolled for Pre-Exposure Prophylaxis
Gilead Study DirectorStudy DirectorGilead Sciences
343 Previous Clinical Trials
183,540 Total Patients Enrolled

Media Library

Lenacapavir (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04925752 — Phase 3
Pre-Exposure Prophylaxis Research Study Groups: PK Tail Phase, LEN Open-Label Extension (OLE) Phase, Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF, Blinded Phase: Placebo LEN + F/TDF
Pre-Exposure Prophylaxis Clinical Trial 2023: Lenacapavir Highlights & Side Effects. Trial Name: NCT04925752 — Phase 3
Lenacapavir (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04925752 — Phase 3
Pre-Exposure Prophylaxis Patient Testimony for trial: Trial Name: NCT04925752 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies in this clinical research program?

"Yes, the clinicaltrials.gov website confirms that this trial is open and actively recruiting participants. The study was first posted on June 28th, 2021 and was last updated November 4th, 2022. 61 different centres are looking to enroll a total of 3000 patients."

Answered by AI

In how many different geographic areas is this trial taking place?

"There are 61 locations where this study is running, some of which include Centro San Vincente in El Paso, Texas, Henry Ford Hospital in Detroit, Michigan and KC CARE Health Center in Kansas City, Missouri."

Answered by AI

Is the data on Lenacapavir (LEN) limited to one clinical trial?

"As of right now, 102 clinical trials are underway that focus on Oral Lenacapavir (LEN). Out of those 102 live studies, 32 are in Phase 3. The majority of research surrounding Oral Lenacapavir (LEN) is conducted in Boylston, Massachusetts; however, there are 1,679 locations worldwide where clinical trials for this treatment are taking place."

Answered by AI

What infections does Oral Lenacapavir (LEN) help to fight?

"Oral Lenacapavir (LEN) is an effective treatment against human immunodeficiency virus type 1 (HIV-1), HIV infections, and the transmission of HIV."

Answered by AI

What is the official position of the FDA on LEN?

"There is pre-existing clinical data supporting the safety of LEN, so it was given a score of 3."

Answered by AI

How many people are taking part in this scientific research project?

"This study necessitates 3000 willing and eligible participants. If you meet the requirements, which are detailed on the clinicaltrials.gov website, then you can sign up to participate at various locations such as Centro San Vincente in El Paso, Texas or Henry Ford Hospital in Detroit, Michigan."

Answered by AI

Who else is applying?

What state do they live in?
Other
Texas
Nevada
California
How old are they?
18 - 65
What site did they apply to?
Mills Clinical Research
The Crofoot Research Center, INC
Optimus Medical Group
Other
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
1
0

What questions have other patients asked about this trial?

Can healthy volunteers be apart of this study? How much is it paying? Are there any clinics in Texas?
PatientReceived 1 prior treatment

Why did patients apply to this trial?

I want to try the injectable prep.
PatientReceived 2+ prior treatments

How responsive is this trial?

Typically responds via
Phone Call
Recent research and studies
Plos OneJournal
Proactive Strategies to Optimize Engagement of Black, Hispanic/latinx, Transgender, and Nonbinary Individuals in a Trial of a Novel Agent for HIV Pre-exposure Prophylaxis (prep)
Cespedes, Michelle, Moupali Das, J. Carlo Hojilla, Jill Blumenthal, Karam Mounzer, Moti Ramgopal, Theo Hodge, et al.. 2022. “Proactive Strategies to Optimize Engagement of Black, Hispanic/latinx, Transgender, and Nonbinary Individuals in a Trial of a Novel Agent for HIV Pre-exposure Prophylaxis (prep)”. Edited by Peter A. Newman. Plos One. Public Library of Science (PLoS). doi:10.1371/journal.pone.0267780.
clinicaltrials.govStudy
Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection
2021. "Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04925752.
All > Rsv > Aids
~628 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top